Projects / Programmes
THE ROLE OF CARDIOVASCULAR RISK FACTORS IN DIALYSIS PATIENTS
Code |
Science |
Field |
Subfield |
3.01.00 |
Medical sciences |
Microbiology and immunology |
|
Code |
Science |
Field |
B530 |
Biomedical sciences |
Cardiovascular system |
end stage renal failure, hypertension, atherosclerosis, left venticular hypertrophy, anemia, dyslipidemia, microinflammation
Researchers (4)
no. |
Code |
Name and surname |
Research area |
Role |
Period |
No. of publicationsNo. of publications |
1. |
07616 |
MSc Maksimiljan Gorenjak |
Human reproduction |
Researcher |
2003 - 2004 |
206 |
2. |
15751 |
PhD Radovan Hojs |
Metabolic and hormonal disorders |
Head |
2003 - 2004 |
795 |
3. |
02053 |
PhD Ivan Krajnc |
Microbiology and immunology |
Researcher |
2003 - 2004 |
615 |
4. |
15750 |
PhD Artur Pahor |
Microbiology and immunology |
Researcher |
2003 - 2004 |
313 |
Organisations (1)
Abstract
Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patients with end stage renal failure (ESRD) on dialysis. CVD morbidity is approximately 10-20 times higher in patients with ESRD compared with that in the general population, but in young dialysis patients between 25 and 34 years is annual mortality from CVD up to 1000 times higher than in the general population. This project is prospective research, which will define the role of hypertension, one of the main risk factors for CVD in dialysis patients. In study, we will define association between interdialytic values of blood pressure and mortality, particularly which values of blood presssure between two dialytic procedures or during dialysis and/or 24 or 48 hours measurement of blood pressure are most associated with morbidity and mortality of dialysis patients. We will also define frequence and stage of left ventricular hypertrophy (LVH), which is good predictor for CVD and association between LVH and hypertension, anemia, dyslipidemia, homocystein and secundary hyperparathyroidism. We will also define the role of microinflammation, that plays important role in the process of atherosclerosis.We will also make complete ophtalmological examination in all dialysis patients. This research is intented to define the risk factors for CVD in dialysis patients, which influence on survivor and quality of life of this patients.